Literature DB >> 19538929

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Greg M Delgoffe1, Thomas P Kole, Yan Zheng, Paul E Zarek, Krystal L Matthews, Bo Xiao, Paul F Worley, Sara C Kozma, Jonathan D Powell.   

Abstract

Effector T cell differentiation requires the simultaneous integration of multiple, and sometimes opposing, cytokine signals. We demonstrated mTOR's role in dictating the outcome of T cell fate. mTOR-deficient T cells displayed normal activation and IL-2 production upon initial stimulation. However, such cells failed to differentiate into T helper 1 (Th1), Th2, or Th17 effector cells. The inability to differentiate was associated with decreased STAT transcription factor activation and failure to upregulate lineage-specific transcription factors. Under normally activating conditions, T cells lacking mTOR differentiated into Foxp3(+) regulatory T cells. This was associated with hyperactive Smad3 activation in the absence of exogenous TGF-beta. Surprisingly, T cells selectively deficient in TORC1 do not divert to a regulatory T cell pathway, implicating both TORC1 and TORC2 in preventing the generation of regulatory T cells. Overall, our studies suggest that mTOR kinase signaling regulates decisions between effector and regulatory T cell lineage commitment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538929      PMCID: PMC2768135          DOI: 10.1016/j.immuni.2009.04.014

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  36 in total

Review 1.  The induction and maintenance of T cell anergy.

Authors:  Jonathan D Powell
Journal:  Clin Immunol       Date:  2006-04-03       Impact factor: 3.969

Review 2.  Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.

Authors:  J Avruch; K Hara; Y Lin; M Liu; X Long; S Ortiz-Vega; K Yonezawa
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

3.  A role for mammalian target of rapamycin in regulating T cell activation versus anergy.

Authors:  Yan Zheng; Samuel L Collins; Michael A Lutz; Amy N Allen; Thomas P Kole; Paul E Zarek; Jonathan D Powell
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

4.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

Authors:  Zhihong Zeng; Dos D Sarbassov; Ismael J Samudio; Karen W L Yee; Mark F Munsell; C Ellen Jackson; Francis J Giles; David M Sabatini; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

Review 5.  mTOR and cancer: insights into a complex relationship.

Authors:  David M Sabatini
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

6.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

Authors:  David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini
Journal:  Dev Cell       Date:  2006-12       Impact factor: 12.270

Review 7.  Regulatory T cells in the periphery.

Authors:  Jens Lohr; Birgit Knoechel; Abul K Abbas
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

8.  Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses.

Authors:  Timothy L Denning; Yi-chong Wang; Seema R Patel; Ifor R Williams; Bali Pulendran
Journal:  Nat Immunol       Date:  2007-09-16       Impact factor: 25.606

9.  Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.

Authors:  Timothy J Harris; Joseph F Grosso; Hung-Rong Yen; Hong Xin; Marcin Kortylewski; Emilia Albesiano; Edward L Hipkiss; Derese Getnet; Monica V Goldberg; Charles H Maris; Franck Housseau; Hua Yu; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

10.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

Authors:  Stephan Sauer; Ludovica Bruno; Arnulf Hertweck; David Finlay; Marion Leleu; Mikhail Spivakov; Zachary A Knight; Bradley S Cobb; Doreen Cantrell; Eric O'Connor; Kevan M Shokat; Amanda G Fisher; Matthias Merkenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-28       Impact factor: 11.205

View more
  596 in total

1.  Mds3 regulates morphogenesis in Candida albicans through the TOR pathway.

Authors:  Lucia F Zacchi; Jonatan Gomez-Raja; Dana A Davis
Journal:  Mol Cell Biol       Date:  2010-05-10       Impact factor: 4.272

Review 2.  Immunomodulation at epithelial sites by obesity and metabolic disease.

Authors:  Kitty P Cheung; Kristen R Taylor; Julie M Jameson
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

3.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

Review 4.  The role of mTOR in memory CD8 T-cell differentiation.

Authors:  Koichi Araki; Ben Youngblood; Rafi Ahmed
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

5.  Targeted immunosuppression: no longer naïve.

Authors:  Robert S Hagan; Jonathan D Powell
Journal:  Clin Immunol       Date:  2011-10-25       Impact factor: 3.969

6.  Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.

Authors:  Mohsen Ibrahim; Davide Scozzi; Kelsey A Toth; Donatella Ponti; Daniel Kreisel; Cecilia Menna; Elena De Falco; Antonio D'Andrilli; Erino A Rendina; Antonella Calogero; Alexander S Krupnick; Andrew E Gelman
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

Review 7.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

Review 9.  Differential T-cell receptor signals for T helper cell programming.

Authors:  Penelope A Morel
Journal:  Immunology       Date:  2018-05-25       Impact factor: 7.397

Review 10.  Metabolism of inflammation limited by AMPK and pseudo-starvation.

Authors:  Luke A J O'Neill; D Grahame Hardie
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.